PT  - JOURNAL ARTICLE
AU  - Ali Berkant Avci
AU  - Eugen Feist
AU  - Gerd-R Burmester
TI  - Biologicals in rheumatoid arthritis: current and future
AID  - 10.1136/rmdopen-2015-000127
DP  - 2015 Aug 01
TA  - RMD Open
PG  - e000127
VI  - 1
IP  - 1
4099  - http://rmdopen.bmj.com/content/1/1/e000127.short
4100  - http://rmdopen.bmj.com/content/1/1/e000127.full
SO  - RMD Open2015 Aug 01; 1
AB  - The aim of the review is to highlight the current knowledge about established and new biologicals and to summarise recent advances by focusing on comparative efficacy, safety and possible discontinuation of treatment in patients with rheumatoid arthritis (RA). Up to now, comparative analyses showed only minor differences with respect to efficacy and safety among the established biologicals. Studies confirmed the excellent drug retention rate as well as efficacy and safety of approved biologicals including their use in monotherapy. Tapering and in some instances discontinuation of biologicals is possible in disease remission. In case of relapse, patients usually show full response after reintroduction of the same compound. The development of biologicals continues fast with several new biologicals targeting different or established cytokines or cellular subsets of the immune system. With several new biologicals in the pipeline and different formulations for established compounds, treatment options for RA will become even more versatile and sophisticated. Although we get closer to the aim of decreasing the proportion of refractory patients, many questions have to be addressed in the near future regarding emerging biosimilars and biologicals with new modes of action.